BioLine Rx (BioLine Rx) Cash And Cash Equivalents : $4.26 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Cash And Cash Equivalents?

BioLine Rx's quarterly cash and cash equivalents declined from Jun. 2023 ($10.10 Mil) to Sep. 2023 ($7.73 Mil) but then stayed the same from Sep. 2023 ($7.73 Mil) to Dec. 2023 ($4.26 Mil).

BioLine Rx's annual cash and cash equivalents declined from Dec. 2021 ($12.99 Mil) to Dec. 2022 ($10.59 Mil) and declined from Dec. 2022 ($10.59 Mil) to Dec. 2023 ($4.26 Mil).

BioLine Rx Cash And Cash Equivalents Historical Data

The historical data trend for BioLine Rx's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Cash And Cash Equivalents Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

5.30

16.83

12.99

10.59

4.26

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															10.59	9.07	10.10	7.73	4.26

BioLine Rx Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

BioLine Rx (NAS:BLRX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

BioLine Rx Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.